Journal of Regenerative Medicine

Editorial

A SCITECHNOL JOURNAL

mRNA-Based Therapies: Applications in Gene Editing and Regenerative Medicine

Bolaji Abubakar*

Division of Regenerative Medicine, University of Lagos, Nigeria

***Corresponding author:** Bolaji Abubakar, Division of Regenerative Medicine, University of Lagos, Nigeria, E-mail: bolaji@unilag.edu.ng

Citation: Abubakar B (2024) mRNA-Based Therapies: Applications in Gene Editing and Regenerative Medicine. J Regen Med 13:6.

Received: 01-Nov-2024, Manuscript No. JRGM-24-152620, **Editor assigned:** 02-Nov-2024, PreQC No. JRGM-24-152620 (PQ), **Reviewed:** 16-Nov-2024, QC No. JRGM-24-152620, **Revised:** 22-Nov-2024, Manuscript No. JRGM-24-152620 (R), **Published:** 27-Nov-2024, DOI:10.4172/2325-9620.1000342

Introduction

Messenger RNA (mRNA)-based therapies have gained immense popularity in recent years, especially following the success of mRNA vaccines in combating the COVID-19 pandemic. However, the potential of mRNA extends far beyond infectious diseases, offering exciting applications in gene editing and regenerative medicine. As a transient intermediary in the central dogma of molecular biology, mRNA serves as a crucial link between DNA and proteins, making it a versatile tool for introducing therapeutic instructions into cells. This article delves into the emerging roles of mRNA in gene editing and regenerative medicine, exploring its promise, challenges, and future potential [1].

At its core, mRNA carries genetic instructions from the DNA in the cell nucleus to the ribosomes, where proteins are synthesized. In mRNA-based therapies, synthetic mRNA is introduced into cells, enabling the production of specific proteins that can trigger desired biological processes. Unlike traditional gene therapies, mRNA does not integrate into the genome, reducing the risk of unwanted mutations. Additionally, because mRNA is a transient molecule, it allows for temporal control over protein production, which is particularly advantageous in therapeutic applications [2].

One of the most promising applications of mRNA technology lies in gene editing, where it is used to deliver the components necessary for genome modification. The CRISPR-Cas9 system, a revolutionary tool for gene editing, requires both a guide RNA and the Cas9 protein to induce targeted DNA cuts. mRNA offers a safer, more efficient way to deliver these elements. By encoding the Cas9 protein and guide RNA sequences, mRNA enables precise gene editing without the need for viral vectors, which are commonly used in DNA-based gene therapies [3].

This approach has already shown great potential in treating genetic disorders such as sickle cell anemia and muscular dystrophy. In these conditions, mRNA-based CRISPR-Cas9 therapies can correct defective genes by introducing temporary molecular scissors that repair the underlying mutations. Furthermore, the transient nature of mRNA minimizes the risk of long-term side effects, which is a significant advantage over other gene-editing methods [4].

Regenerative medicine focuses on replacing or repairing damaged tissues and organs, often by stimulating the body's natural healing processes. mRNA-based therapies offer a powerful tool for regenerative applications by enabling the controlled expression of growth factors, cytokines, or other signaling molecules that drive tissue regeneration. For example, mRNA encoding for vascular endothelial growth factor (VEGF) has been explored for promoting blood vessel formation in patients with ischemic heart disease, enhancing tissue repair by improving oxygen and nutrient supply to damaged areas [5].

Additionally, mRNA can be used to reprogram cells into different cell types, a critical aspect of regenerative medicine. By delivering mRNA that encodes transcription factors, researchers can convert fibroblasts (connective tissue cells) into induced pluripotent stem cells (iPSCs), which have the capacity to differentiate into any cell type. This approach holds immense potential for generating patient-specific stem cells that can be used for personalized tissue repair without the risk of immune rejection [6].

mRNA-based therapies are also being explored for enhancing wound healing, especially in chronic wounds such as diabetic ulcers. By delivering mRNA encoding for proteins that promote cell proliferation, migration, and tissue remodeling, these therapies can accelerate the wound healing process. For instance, mRNA encoding for collagen or growth factors can enhance the formation of extracellular matrix and stimulate angiogenesis, leading to faster tissue repair. Moreover, mRNA therapies can be tailored to deliver multiple therapeutic proteins simultaneously, addressing various aspects of wound healing in a coordinated manner. This multi-faceted approach makes mRNA an attractive option for treating complex wounds that require both structural and functional restoration [7].

One of the primary challenges in mRNA-based therapies is the body's natural immune response to foreign RNA molecules. Unmodified mRNA can be recognized as a pathogen-associated molecule, triggering an immune response that leads to its rapid degradation. To overcome this challenge, researchers have developed various strategies, such as chemical modifications to the mRNA structure, lipid nanoparticle (LNP) encapsulation, and the use of immune-suppressive adjuvants. These advancements have improved the stability and delivery of mRNA, making it more suitable for therapeutic applications in both gene editing and regenerative medicine [8].

Effective delivery of mRNA into target cells is crucial for its therapeutic success. Naked mRNA is rapidly degraded in the bloodstream, and ensuring it reaches the intended tissues without eliciting an excessive immune response requires sophisticated delivery platforms. Lipid nanoparticles (LNPs) have emerged as one of the most effective delivery vehicles for mRNA, protecting it from

degradation and facilitating its uptake by cells. Recent innovations in LNP technology have significantly improved the delivery of mRNA-based therapies. For example, LNPs can be designed to target specific tissues or cell types, increasing the precision of gene editing or tissue regeneration. Researchers are also exploring biodegradable polymer-based nanoparticles and exosome-based systems as alternative delivery methods to further enhance the efficacy and safety of mRNA therapies [9].

Despite the promise of mRNA-based therapies, several safety and regulatory challenges remain. The transient nature of mRNA is beneficial in terms of reducing long-term side effects, but it also requires repeated administrations to achieve sustained therapeutic effects. Additionally, while the risk of insertional mutagenesis is lower compared to DNA-based therapies, the immune response to mRNA and its delivery systems must be carefully managed to avoid adverse effects. Regulatory agencies are closely monitoring the development of mRNA-based therapies, especially in the context of gene editing, where ethical concerns about genetic modifications are heightened. Ensuring that these therapies meet stringent safety and efficacy standards will be crucial for their successful translation from the lab to the clinic [10].

Conclusion

mRNA-based therapies are opening new frontiers in both gene editing and regenerative medicine, offering a versatile and dynamic platform for treating diseases at their molecular roots. By leveraging the body's natural protein synthesis machinery, mRNA holds the potential to repair damaged tissues, correct genetic mutations, and even reprogram cells. While challenges remain, particularly in terms of delivery and immune response, ongoing research and technological advancements are steadily unlocking the full potential of mRNA therapies. As these innovations continue to progress, mRNA-based treatments could one day become the foundation of a new era in precision medicine, offering hope for conditions once thought to be incurable.

References

1. Müller K. Müller K. Drugs: From Discovery to Approval . By Rick Ng.
2. Kesik□Brodacka M. Progress in biopharmaceutical development (2018) Biotechnol Appl Biochem;65(3):306-22.
3. Deshaies RJ (2020) Multispecific drugs herald a new era of biopharmaceutical innovation. Nat;580(7803):329-38.
4. Muller PY, Milton MN (2012) The determination and interpretation of the therapeutic index in drug development. Nat Rev Drug Discov;11(10):751-61.
5. Chabanovska O, Galow AM, David R, Lemcke H (2021) mRNA–a game changer in regenerative medicine, cell-based therapy and reprogramming strategies. Adv Drug Deliv Rev;179:114002.
6. Dimitrov DS (2012) Therapeutic proteins. Therapeutic Proteins: Methods and Protocols:1-26.
7. Crick F (1970) Central dogma of molecular biology. Nat;227(5258):561-3.
8. Van Hoecke L, Roose K (2019) How mRNA therapeutics are entering the monoclonal antibody field. J Transl Med;17(1):54.
9. Furuichi Y, Miura KI (1975) A blocked structure at the 5′ terminus of mRNA from cytoplasmic polyhedrosis virus. Nat;253(5490):374-5.
10. Dimitriadis GJ (1978) Translation of rabbit globin mRNA introduced by liposomes into mouse lymphocytes. Nat;274(5674):923-4.